明星大侦探
GT Voice: Chinese investment could help Germany stabilize its talent base_我的网站
A |
Germany's industrial woes have increasingly become a hot topic of discussion. The latest Engineer Monitor report from professional association Verein Deutscher Ingenieure and the German Economic Institute offers a new look at the issue.
The report showed that there were 58,392 unemployed individuals in the engineering and information technology (IT) professions in the fourth quarter of 2025, the highest level since the survey began in 2011.
Compared with the previous year, the number of unemployed increased by 16.7 percent, according to German media reports on Sunday.
These figures lay bare the challenges confronting the country's manufacturing sector. The reasons for the industrial woes are multiple. The soaring energy costs caused by geopolitical conflicts, the decline in exports caused by rising protectionism and low external demand, and the structural pain caused by industrial chain restructuring are all squeezing the space of German manufacturing.
Manufacturing is the backbone of Germany's economy, and engineers and IT specialists constitute the core force that sustains this pillar. For decades, the country's reputation for "Made in Germany" excellence was built on the expertise of these skilled professionals. Regardless of the macroeconomic ups and downs, preserving the stability and continuity of its industrial talent pool represents a strategic bottom line for Germany.
Should large numbers of highly skilled technical professionals leave the industry or sit idle, industrial research and development (R&D) and production cycles will be disrupted. Over the longer term, such a waste of human capital will erode Germany's industrial innovation capacity and, ultimately, undermine the foundations of its global competitiveness.
In this context, the urgent task for Germany is to create sufficient quality positions for its technical talent. Should it fail to do so in the short term, then Germany needs to embrace a more open‑minded development approach. Shoring up its manufacturing base cannot be achieved solely through protecting domestic companies; it also requires a significant expansion of effective investment to create enough high‑quality jobs that can attract and retain skilled talent.
This is exactly where China‑Germany cooperation could deliver tangible results. According to the FDI Report 2025 published by Germany Trade & Invest (GTAI), the total number of foreign investment projects in Germany fell 9.3 percent overall to 1,564 in 2025. Nonetheless, Chinese companies became the largest source of foreign investment projects in Germany in 2025, overtaking the US for the first time since 2017.
Chinese companies launched 228 investment projects in Germany in 2025, up 14.6 percent year-on-year. More than one in five Chinese investment projects involved production and R&D activities, above the overall average for foreign investment projects in Germany. This is a sign that Chinese firms are deepening their integration into the local industrial base, according to GTAI.
Observers noted the trend, pointing out that China is becoming an important force in driving German re‑industrialization. In industries where Germany urgently needs to rebuild its competitive edge, such as electric vehicles, batteries, energy technology, digital manufacturing, and automation, China is emerging as an increasingly significant complementary partner. In these critical areas that will determine industrial competitiveness in the coming decades, the relationship between China and Germany is not merely one of rivalry; there are clear and substantial complementarities. Germany still boasts world‑leading engineering expertise, precision manufacturing capabilities, and a strategic location at the heart of the European market.
China has complete and highly integrated supply chains for raw materials and intermediate goods and large capacity for increasing production. When Chinese automakers set up R&D centers in Germany, or when Chinese tech firms collaborate with German factories to build smart production lines, the beneficiaries are not only the Chinese companies but also the German engineers who would otherwise face redundancy.
Cross‑border investment cannot flourish without a sound policy environment. Chinese companies are apparently willing to develop in Germany, but it can only happen on the premise that the German side provides a fair, reasonable and predictable business environment, reduces non-market interference in commercial activities, and allows capital to operate in accordance with market rules.
If the two countries are able to reach a deeper level of cooperation in investment, many of Germany's trade‑related concerns may well find more pragmatic solutions. The deep integration of industrial value chains would facilitate two‑way trade, creating renewed momentum for German exports of machinery, vehicles, chemicals, and other competitive products to China.
。 Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。
B |
Current article:http://kfq.zhouangnaoguangsundianzhenmou.cfd/list_l4kdt/2bj.html
Published on:10:44:14